These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 28294420)

  • 1. Chronic urticaria in the real-life clinical practice setting in Sweden, Norway and Denmark: baseline results from the non-interventional multicentre AWARE study.
    Thomsen SF; Pritzier EC; Anderson CD; Vaugelade-Baust N; Dodge R; Dahlborn AK; Vestergaard C
    J Eur Acad Dermatol Venereol; 2017 Jun; 31(6):1048-1055. PubMed ID: 28294420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. H1-antihistamine-refractory chronic spontaneous urticaria: it's worse than we thought - first results of the multicenter real-life AWARE study.
    Maurer M; Staubach P; Raap U; Richter-Huhn G; Bauer A; Ruëff F; Jakob T; Yazdi AS; Mahler V; Wagner N; Lippert U; Hillen U; Schwinn A; Pawlak M; Behnke N; Chaouche K; Chapman-Rothe N
    Clin Exp Allergy; 2017 May; 47(5):684-692. PubMed ID: 28160338
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antihistamine-resistant chronic spontaneous urticaria: 1-year data from the AWARE study.
    Maurer M; Raap U; Staubach P; Richter-Huhn G; Bauer A; Oppel EM; Hillen U; Baeumer D; Reinhardt M; Chapman-Rothe N
    Clin Exp Allergy; 2019 May; 49(5):655-662. PubMed ID: 30415478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical characteristics and management of chronic spontaneous urticaria in patients refractory to H
    Chu CY; Al Hammadi A; Agmon-Levin N; Atakan N; Farag A; Arnaout RK; Kannenberg S; Kulthanan K; Mubarak A; Zaitoun F; Crowe S; Malfait S; Cooke K; Dekker EL
    World Allergy Organ J; 2020 Apr; 13(4):100117. PubMed ID: 32382379
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Socio-economic burden and resource utilisation in Italian patients with chronic urticaria: 2-year data from the AWARE study.
    Rossi O; Piccirillo A; Iemoli E; Patrizi A; Stingeni L; Calvieri S; Gola M; Dapavo P; Cristaudo A; Zichichi L; Losappio L; Saccheri F; Pastorello EA
    World Allergy Organ J; 2020 Dec; 13(12):100470. PubMed ID: 33343800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic urticaria in the real-life clinical practice setting in the UK: results from the noninterventional multicentre AWARE study.
    Savic S; Leeman L; El-Shanawany T; Ellis R; Gach JE; Marinho S; Wahie S; Sargur R; Bewley AP; Nakonechna A; Randall R; Fragkas N; Somenzi O; Marsland A
    Clin Exp Dermatol; 2020 Dec; 45(8):1003-1010. PubMed ID: 32246853
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antihistamine-resistant chronic spontaneous urticaria remains undertreated: 2-year data from the AWARE study.
    Maurer M; Costa C; Gimenez Arnau A; Guillet G; Labrador-Horrillo M; Lapeere H; Meshkova R; Savic S; Chapman-Rothe N
    Clin Exp Allergy; 2020 Oct; 50(10):1166-1175. PubMed ID: 32735720
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Specialized Therapeutic Approach to Chronic Urticaria Refractory to H1-Antihistamines Improves Disease Burden: The Spanish AWARE Experience.
    Gimenez-Arnau A; Bartra J; Ferrer M; Jauregui I; Borbujo J; Figueras I; Muñoz-Bellido FJ; Pedraz J; Serra-Baldrich E; Tejedor-Alonso MA; Velasco M; Terradas P; Labrador M
    J Investig Allergol Clin Immunol; 2022 Jun; 32(3):191-199. PubMed ID: 33349612
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chronic urticaria treatment patterns and changes in quality of life: AWARE study 2-year results.
    Maurer M; Giménez-Arnau A; Ensina LF; Chu CY; Jaumont X; Tassinari P
    World Allergy Organ J; 2020 Sep; 13(9):100460. PubMed ID: 32983330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Improvement of patient outcomes following therapeutic optimization of chronic urticaria: two-year data from France as part of the international real-life AWARE study.
    Giordano-Labadie F; Becherel PA; Pralong P; Outtas O; Ruer-Mulard M; Berard F; Greco M; Lacour JP; Debons-Peyroutet M; Pelvet B; Lamirand A; Guillet G
    Eur J Dermatol; 2021 Apr; 31(2):217-224. PubMed ID: 34001470
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The burden of chronic urticaria: French baseline data from the international real-life AWARE study.
    Guillet G; Bécherel PA; Pralong P; Delbarre M; Outtas O; Martin L; Pelvet B; Gharbi H; Giordano-Labadie F
    Eur J Dermatol; 2019 Feb; 29(1):49-54. PubMed ID: 30827942
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differences in chronic spontaneous urticaria between Europe and Central/South America: results of the multi-center real world AWARE study.
    Maurer M; Houghton K; Costa C; Dabove F; Ensina LF; Giménez-Arnau A; Guillet G; Konstantinou GN; Labrador-Horrillo M; Lapeere H; Meshkova R; Pastorello EA; Velásquez-Lopera M; Tamayo Quijano LM; Vestergaard C; Chapman-Rothe N
    World Allergy Organ J; 2018; 11(1):32. PubMed ID: 30464782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Omalizumab rapidly improves angioedema-related quality of life in adult patients with chronic spontaneous urticaria: X-ACT study data.
    Staubach P; Metz M; Chapman-Rothe N; Sieder C; Bräutigam M; Maurer M; Weller K
    Allergy; 2018 Mar; 73(3):576-584. PubMed ID: 29058822
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of omalizumab on angioedema in H1 -antihistamine-resistant chronic spontaneous urticaria patients: results from X-ACT, a randomized controlled trial.
    Staubach P; Metz M; Chapman-Rothe N; Sieder C; Bräutigam M; Canvin J; Maurer M
    Allergy; 2016 Aug; 71(8):1135-44. PubMed ID: 27010957
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chronic Urticaria in the Real-Life Clinical Practice Setting in Portugal: Baseline Results from the Non-Interventional Multicentre AWARE Study.
    Costa C; Rosmaninho I; Guilherme A; Ferreira J; Antunes J; Pina A; Prates S; Marques JG; Azevedo F; Cunha AP; Brito C; Massa A; Sousa JT; Velho GC; Raposo I; Pinto GM; Sousa V; Martins AR
    Acta Med Port; 2019 Feb; 32(2):133-140. PubMed ID: 30896394
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treating chronic urticaria refractory to H1-antihistamines in Russia: data from the AWARE study.
    Danilycheva I; Emelyanov A; Meshkova R; Ukhanova O; Abdrakhmanov A; Litvin L
    Postepy Dermatol Alergol; 2022 Jun; 39(3):509-516. PubMed ID: 35950113
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of chronic inducible urticaria according to the guidelines: A prospective controlled study.
    Kocatürk E; Can PK; Akbas PE; Copur M; Degirmentepe EN; Kızıltac K; Singer R
    J Dermatol Sci; 2017 Jul; 87(1):60-69. PubMed ID: 28314658
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of omalizumab on quality of life and its predictors in patients with chronic spontaneous urticaria: Real-life data.
    Salman A; Demir G; Bekiroglu N
    Dermatol Ther; 2019 Jul; 32(4):e12975. PubMed ID: 31145524
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omalizumab in patients with chronic spontaneous urticaria nonresponsive to H1-antihistamine treatment: results of the phase IV open-label SUNRISE study.
    Bérard F; Ferrier Le Bouedec MC; Bouillet L; Reguiai Z; Barbaud A; Cambazard F; Milpied B; Pelvet B; Kasujee I; Gharbi H; Lacour JP
    Br J Dermatol; 2019 Jan; 180(1):56-66. PubMed ID: 29927483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The burden of symptomatic patients with chronic spontaneous urticaria: a real-world study in Korea.
    Ye YM; Koh YI; Choi JH; Kim MA; Park JW; Kim TB; Nam YH; Chang YS; Park HS
    Korean J Intern Med; 2022 Sep; 37(5):1050-1060. PubMed ID: 36068718
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.